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Abstract: In glioma surgery, Protoporphyrin IX (PpIX) fluorescence may 
identify residual tumor that could be resected while minimizing damage to 
normal brain. We demonstrate that improved sensitivity for wide-field 
spectroscopic fluorescence imaging is achieved with minimal disruption to 
the neurosurgical workflow using an electron-multiplying charge-coupled 
device (EMCCD) relative to a state-of-the-art CMOS system. In phantom 
experiments the EMCCD system can detect at least two orders-of-
magnitude lower PpIX. Ex vivo tissue imaging on a rat glioma model 
demonstrates improved fluorescence contrast compared with neurosurgical 
fluorescence microscope technology, and the fluorescence detection is 
confirmed with measurements from a clinically-validated spectroscopic 
probe. Greater PpIX sensitivity in wide-field fluorescence imaging may 
improve the residual tumor detection during surgery with consequent 
impact on survival. 
©2015 Optical Society of America 
OCIS codes: (170.3890) Medical optics instrumentation; (170.6280) Spectroscopy, 
fluorescence and luminescence. 
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1. Introduction 
The goal of neurosurgery in brain tumor management is to maximize the extent of tumor 
resection while minimizing functional impairment secondary to surgery. Standard surgical 
equipment comprises a white-light neurosurgical microscope and a neuronavigation unit to 
guide surgery based on preoperative magnetic resonance imaging (MRI). The use of 
preoperative MRI improves the accuracy and safety of surgical resections using spatial co-
registration of MRI scans with intraoperative magnified bright-field images taken in real time 
during surgery. Indeed, image-guided neurosurgery has increased the completeness of tumor 
resection as determined by comparing tumor tissue visible in preoperative relative to 
postoperative MRI [1]. 
More recently, intraoperative fluorescence imaging based on the optical contrast of 
molecules such as indocyanine green, fluorescein and protoporphyrin IX (PpIX) has emerged 
[2]. PpIX is synthesized and retained preferentially in tumor cells following administration of 
the pro-drug 5-aminolevulinic acid (ALA). The biological origin of the optical contrast varies 
between fluorophores, each providing different and potentially complementary clinical 
information. For example, preferential accumulation of PpIX in tumor cells results in part 
from differences in heme biosynthesis and pro-drug uptake. Glioblastoma resection surgery 
guided by the red fluorescence of PpIX upon violet light excitation has been demonstrated in 
controlled clinical trials to improve the completeness of tumor resection relative to resections 
based solely on bright-field, white-light visualization [3]. 
For the majority of clinical studies of ALA-PpIX guided resection of brain tumors, 
fluorescence detection is achieved with a commercial neurosurgical microscope [4]. The 
emitted fluorescence is detected by a color RGB camera or by the naked eye through the 
oculars of the microscope. The resection is thus guided by subjective visual assessment of the 
fluorescence images in real time, referred to as qualitative fluorescence imaging. 
Clinical reports have suggested that the metabolic marker PpIX aids in surgical guidance 
of other brain pathologies, including meningioma and metastatic brain lesions [5–8]. It has 
also been used in other organs for tumor localization and treatment guidance [9]. However, 
qualitative fluorescence imaging is intrinsically limited in sensitivity and specificity. The 
sensitivity, i.e. the ability to detect (residual) tumor, is hampered by the limited detection 
efficiency of CCD cameras (e.g., read-out noise, quantum efficiency), the presence of the 
leakage reflectance signals into the detection path (background), and the confounding effects 
of intrinsic tissue optical properties [6]. Specificity is negatively impacted by the lack of 
spectral resolution when using high-pass interference filtering. Importantly, this limitation 
prevents subtraction of tissue auto-fluorescence background, which places a lower limit on 
the concentration of the exogenous fluorophore that can be detected and does not allow 
simultaneous imaging of multiple fluorophores. Moreover, studies using point fluorescence 
measurements combined with diffuse reflectance spectroscopy suggest that low-grade 
gliomas also produce diagnostic levels of ALA-induced PpIX but that the signals are too low 
to be detected with standard qualitative wide-field fluorescence imaging [6,10]. Patients with 
glioblastomas (WHO grade 4 gliomas [11]) do see some survival benefits based on 
maximizing extent of resection [12,13] and complete resection is a major factor in preventing 
recurrence and improving survival for grade 4 gliomas [14]. Although the specificity of PpIX 
uptake in glioblastomas can inhibit the ability to maximize extent of resection, particularly in 
areas of edema, providing more sensitive fluorescence imaging can give the surgeon 
additional information to make more informed decisions during surgery. Completeness of 
resection for low-grade gliomas can considerably extend survival and potentially be curative 
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[15–17], motivating the need to improve current fluorescence imaging during brain (and 
other) tumor resections [18]. 
We have previously reported techniques and instruments to circumvent some of the 
limitations of qualitative fluorescence imaging. We developed a contact fiberoptic probe 
combining fluorescence and diffuse reflectance spectroscopy, allowing for the correction of 
light attenuation by the tissue on fluorescence signal and giving absolute PpIX tissue 
concentration [19,20]. With a contact fiberoptic probe, we have detected PpIX concentrations 
as low as ∼1 ng/ml in brain tissue phantoms under violet light excitation and in clinical in 
vivo clinical measurements have shown ALA-PpIX accumulation in low-grade glioma as low 
as ~1–10 ng/ml [6,19]. Building upon this work, we then developed a modular, wide-field 
spectroscopic imaging system using a scientific CMOS (sCMOS) camera integrated onto an 
optical port of a commercial fluorescence neurosurgical microscope [21]. In other work, we 
used a CCD-based system for glioblastoma resection in patients, demonstrating that it is able 
to detect brain tumor margins beyond what can be detected with qualitative fluorescence 
imaging coupled with neuronavigation and MRI [20]. However, when compared with the 
contact fiberoptic point probe system, the sensitivity of the both the CMOS and CCD systems 
is at least 10 to 20 times less, due primarily to the camera read-out noise [21], compromising 
the ability to detect the low levels of ALA-PpIX often present in low-grade gliomas. An 
electron-multiplying charge-couple device (EMCCD) allows for fast, high performance signal 
detection, particularly for low exposure times or in low-light conditions [22–24], and has seen 
use in spectrally resolved fluorescence tomography [25] and fluorescence correlation 
spectroscopy [26,27]. In this report we demonstrate that wide-field spectroscopic detection of 
PpIX using the state-of-the-art sCMOS system can be further improved with an EMCCD 
imaging detector, and that this technology can also be seamlessly integrated into the 
neurosurgical workflow. 
2. Methods 
2.1. System setup 
The new fluorescence system is shown in Fig. 1 and consists of custom optical adapters, the 
same LCTF as used in the sCMOS system, a coherent fiber-optic imaging bundle (Schott) and 
an hNü EMCCD camera (Nüvü Camēras). The custom adapters couple the imaging bundle, 
LCTF and camera to an optical port on a commercial neurosurgical microscope (BLUE 400 
Pentero, Carl Zeiss Meditec) equipped with a blue light source and fluorescence detection 
capabilities. 
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 Fig. 1. Schematic of the imaging set up used to evaluate the performance of the EMCCD- and 
CMOS-based spectral imaging systems connected to different ports on a commercial 
neuroscurgical microscope. The photograph shows the EMCCD system, including the coherent 
imaging bundle used for remote light detection. 
An imaging bundle is required, because the size (15.5 × 15.5 × 17.8 cm) and weight (4.5 
kg) of the EMCCD camera prevents it from being directly mounted to the microscope’s 
optical port. The 91 cm long bundle comprises a square array (1.6 cm2) of 400 × 400 optical 
fibers each of 60 µm core diameter. The LCTF performs single-band filtering (∼7 nm full-
width at half maximum) in the visible range (400-720 nm) and has a wavelength-dependent 
transmittance (maximum 64% at 710 nm and out-of-band rejection ∼4 OD). The EMCCD 
camera has 512 × 512 pixels, 92% peak quantum efficiency (QE), effective read-out noise of 
<0.1e- at 20 MHz, and a thermal noise D = 0.0002 e-/pixel/s at its lowest cooling temperature 
of −85°C. Custom LabView software (National Instruments, Austin, TX) controls data 
acquisition, processing and image display. The amplification gain on the EMCCD camera can 
be set to values as high as G = 5000 but, unlike the sCMOS system, is affected by an F = 2  
excess noise factor induced by the stochastic processes in the electron multiplying register 
and by a charge injection noise of C < 0.001 e-/pixel. The EMCCD signal-to-noise ratio 
(SNR) is given by [28] 
 
( )











 + × × + × + + 
 (1) 
The same formula applies for the sCMOS camera, and all parameters for both systems are 
described in Table 1. For the EMCCD system, the dominant sources of noise are charge 
injection noise and to a lesser extent thermal noise. For the sCMOS system, the dominant 
sources of noise are readout noise and thermal noise. 
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Table 1. Descriptions of the parameters used in Eq. (1), with the relevant values for the 
EMCCD and sCMOS systems. 
Parameter Description EMCCD value sCMOS value 
QE Quantum efficiency at peak 92% 60% 
F 
Excess noise factor induced by the 
stochastic process in the electron 
multiplying register 
2  1 
T Image integration time (varies) (varies) 
D Thermal noise 0.0002 e-/pixel/s 0.08 e-/pixel/s 
C Charge injection noise < 0.001 e-/pixel 0 
σ Readout noise 100 e-/pixel 1.5 e-/pixel 
G Amplification gain Up to 5000 1 
IPpIX Fluorescence signal from PpIX - - 
IBkg Non-specific contributions to the 
signal: autofluorescence and ambient 
- - 
PpIX Bkg( )I I QE+ ×  Signal - - 
PpIX Bkg( )I I QE+ ×  Shot noise - - 
2.2. Phantom study 
We devised an experimental protocol to compare quantitatively the sensitivity of the 
EMCCD- and sCMOS-based systems under identical conditions. As illustrated in Fig. 1, the 
systems were simultaneously connected to equivalent optical ports of the neurosurgical 
microscope. A power meter was used to verify that the fraction of signal sent to both optical 
ports is equal, using the same magnification. The violet light source integrated into the 
microscope illuminated tissue-simulating liquid phantoms containing different PpIX 
concentrations. The phantoms also contained a lipoprotein suspension (Intralipid) to provide 
brain tissue-like scattering coefficients at the excitation wavelength (μs’ = 15-25 cm−1 @ 405 
nm) and yellow food coloring (McCormick) as the optical absorber (μa = 20-60 cm−1 @ 405 
nm) [29]. Nine sets of phantoms of different absorption-scattering combinations were 
prepared, each combination being used with 5 different PpIX concentrations: 5 and 1 μg/ml 
and 200, 40 and 8 ng/ml. The optical coefficients at the emission wavelength (600 nm) ranged 
from μa = 0.02 to 0.06 cm−1 and μs’ = 8.7 to 14.5 cm−1. Fluorescence images were acquired 
simultaneously for each phantom with both cameras for integration times (per wavelength) of 
T = 5, 10, 20, 40, and 80 ms. 11 images were acquired from 400 to 430 nm and 41 images 
from 600 to 720 nm with 3 nm spectral resolution, for a total of 52 images. The incident 
excitation light power density was ∼5 mWcm−2 over a circular field of view of 20 cm2 at a 
distance of 30 cm between the microscope condenser lens and the phantom surface. 
Spectroscopic reflectance images were also acquired under white-light illumination. 
Quantitative fluorescence values were computed using previously-reported algorithms [20,30] 
in which the raw fluorescence spectra are normalized with the reflectance spectra to account 
for the spectral distortion caused by tissue absorption and scattering. Spectral un-mixing was 
used to separate the contribution of PpIX from background signal including intrinsic 
fluorescence, using a nonnegative least-squares approach [19,20]. As described previously 
[20,30], a calibration factor was determined from a PpIX dilution experiment that related the 
attenuation-corrected spectra to actual dye concentrations. This procedure produced an 
estimate of PpIX concentration at the tissue surface (in μg/ml) for each image pixel. 
2.3. Ex vivo tissue study 
To test the utility of performing fluorescence imaging enabled by the EMCCD, two female 
Lewis rats (Charles River, QC, Canada) were used under institutional approval (University 
Health Network, Toronto, Canada). For tumor induction, the rats were placed under 4% 
isoflurane anesthesia (oxygen flow at 2 L/min), induced in a chamber and sustained by 1-
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2.5% isoflurane at 1 L/min via a rat-adapted nose cone. The eyes were lubricated with tear 
gel, and the animals were placed on a warming blanket. For each rat, the scalp was shaved 
and disinfected with betadine and isopropanol, followed by a 1.5 cm incision along the 
midline. A 1 mm burr hole was made in the left hemisphere, 3 mm posterior to the bregma 
and 2 mm to the left of the sagittal suture, exposing the dura but leaving it intact. Subsurface 
intracranial brain tumors were induced by injection of 105 RG2 (ATCC CRL-2433) cells in 5 
µL of RPMI-1640 media (Sigma-Aldrich) through the burr hole, at a depth of 2 mm below 
the dura using a 26G Hamilton syringe. Tumors were allowed to grow for 14 days to a size of 
3-4 mm. On the day of surgery, 120 mg/kg of ALA (Sigma-Aldrich) was injected 
intraperitoneally. Four hours post-injection, each rat was sacrificed; the whole brain was 
removed intact and sectioned into 3-4 mm thick slices under subdued light. The brain sections 
were mounted on a tissue cassette and were then frozen in liquid nitrogen/isopentane. 
On the day of imaging, the tissue samples were slowly thawed to room temperature. For 
each of the 7 tissue samples (3 from one animal and 4 from the other), a sequence of 
spectroscopic fluorescence and diffuse reflectance images were acquired using the EMCCD 
from 400 to 430 nm and 600-720 nm with 3 nm spectral resolution. Fluorescence and white-
light images were also acquired using the clinical Zeiss Pentero surgical microscope equipped 
with a 400 nm excitation fluorescence imaging option. The exposure time with the EMCCD 
varied from 10 to 100 ms with a gain of 500. Background images were also taken with no 
excitation light. Each sample lying on one side of the tissue cassette was placed at the same 
position in a box made to isolate the sample from ambient light sources. The sample was 
retained in the cassette to keep it intact. The fluorescence spectra were normalized using the 
reflectance spectra to account for the effects of tissue absorption and scattering, and spectral 
un-mixing was applied to separate the contribution of the fluorophore from background 
signals including tissue autofluorescence, based on the acquired background images with no 
excitation light [19,20]. A hand-held optical probe was used to measure fluorescence in the 
tissue slices. The probe, described previously [19,29], has optical fibers for fluorescence 
excitation at 405 nm, and spectroscopic detection between 430 and 750 nm. The diffuse 
reflectance spectra at two different source-detector fiber separations is also measured and 
used to derive the tissue absorption and scattering properties that are then applied to the 
measured fluorescence spectrum to derive the absolute fluorophore concentration in the 
tissue. For each slice, the probe was placed in contact with the tissue specimen to measure 
fluorescence at a single location. The measurement locations for the probe were chosen as 
positions with high fluorescence observed on the standard qualitative fluorescence image. 
3. Results 
3.1. Phantom study 
Figure 2 shows the fluorescence imaging estimates of PpIX concentration as a function of the 
true values in the phantoms for the two systems using different exposure times. The 
calibration factor allows the x and y axis to be expressed in the same units (μg/ml), while the 
attenuation correction factor brings the data points closer together along the y-axis [30]. 
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 Fig. 2. Recovered values of PpIX concentration versus the known PpIX values in the different 
tissue-simulating phantoms for both the CMOS (a,c) and EMCCD systems (b,d) with 
integration times of 5 ms per wavelength (a,b) and 20 ms per wavelength (c,d). Measurements 
were averaged over a 5 by 5 pixel window in the center of the inclusion. Measurements at each 
PpIX concentration correspond to 9 phantoms with different absorption-scattering 
combinations at 600 nm ranging from μa = 0.02 to 0.06 cm−1 and μs’ = 8.7 to 14.5 cm−1. The 
lines of fit are in red. 
These plots indicate that the quantified fluorescence varies linearly with concentration to 
the lowest PpIX level (8 ng/ml) for the EMCCD system, but the linearity breaks down at 
around 40 ng/ml for the sCMOS system at a 20 ms exposure time (no significant linearity 
observed for a 5 ms exposure time, see below for discussion of the linearity at different 
exposure times). Thus, since the noise floor of the EMCCD system was not reached at the 
lowest concentration, its sensitivity is at least 1-2 orders of magnitude greater than that of the 
sCMOS system, which is the current state-of-the-art for ALA-PpIX fluorescence detection in 
neurosurgical guidance. In fact, the sensitivity is comparable to that of the point probe that 
has a PpIX detection limit ∼1 ng/ml. The R2 values for the fit of estimated vs. true PpIX 
concentration, for the CMOS and EMCCD systems and for each exposure time, are listed in 
Table 2. These quantities were computed based on the residuals for the linear fit of all points 
for a particular exposure time (i.e. the values for all phantoms at all concentrations for one 
exposure time yield a single R2 value). The R2 values for the EMCCD system are 0.89 or 
greater for all exposure times, while those for the CMOS system range from 0.64 to 0.79 for 
exposure times less than 40 ms, demonstrating the improved sensitivity of the EMCCD 
system for fluorescence detection, particularly at lower fluorophore concentrations and for 
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lower exposure times. The R2 value for an 80 ms exposure time is somewhat greater for the 
CMOS system. 
Table 2. R2 values for the fit of quantified PpIX concentration (log) vs true PpIX 
concentration (log) for the CMOS and EMCCD systems at different exposure times. 
Exposure 
time (ms) 
R2 for CMOS 
quantification (a.u.) 
R2 for EMCCD 
quantification (a.u.) 
5 0.64 0.89 
10 0.69 0.91 
20 0.79 0.93 
40 0.92 0.93 
80 0.95 0.92 
Limitations of the sCMOS system sensitivity are further illustrated in the spectra of Fig. 3, 
in which the 635 nm PpIX emission peak cannot be detected even at 40 ng/ml concentration 
for 20 ms exposure time. The PpIX emission peak is not visible with the CMOS system for 
exposure times of 5, 10 and 40 ms (data not shown), whereas the peak is visible for all 
exposure times with the EMCCD system. The increased EMCCD system sensitivity is 
directly related to its multiplication gain that, as shown in Eq. (1), attenuates the read-out 
noise. 
 
Fig. 3. Examples of fluorescence spectra acquired with both imaging systems for 20 ms 
exposure at PpIX concentrations of 40 and 200 ng/ml and with optical properites μa = 0.03 
cm−1 and μs’ = 14.5 cm−1. The measurements were averaged over a 5 by 5 pixel window at the 
center of the inclusion, and the spectra are normalized by reflectance data. 
The results presented here suggest that the excess noise factor, F, and the injection charge 
noise, C, do not meaningfully affect the EMCCD’s detection sensitivity under experimental 
conditions relevant to its intended clinical use. However, larger values of C, as found in other 
EMCCD camera models, could negatively impact performance for PpIX detection. 
3.2. Ex vivo tissue study 
Figure 4 shows images of tissue samples acquired using the surgical microscope’s internal 
RGB camera (TRIO 630 integrated camera system for the Pentero microscope) and the 
fluorescence images acquired with the EMCCD system. In each sample, two areas identified 
by boxes 1 and 2, compare the recovered contrast of the EMCCD system with the visible 
contrast attained through the qualitative fluorescence imaging feature available on the Pentero 
microscope. Contrast ratio (CR) was calculated as the ratio of intensity in box 1 or 2 to the 
intensity in the background box shown in Fig. 4. The background box was selected as an area 
of tissue where negligible fluorescence was observed. 
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 Fig. 4. (a,c) Two ex vivo brain tissue samples containing glioma, as viewed through the 
neurosurgical microscope under violet light excitation. (b,d) show the corresponding images 
for the derived quantitative fluorescence using the EMCCD system. Representative contrast 
ratios (CR) are shown within the tumor. The images have been cropped to highlight the tissue 
samples. 
For the EMCCD, the intensity represents the recovered fluorescence value (as described 
in Materials and Methods). For the microscope, the intensity Im from the surgical 
microscope’s internal RGB camera was calculated as the luminance [31] in order to represent 
the visibility of each color component in the fluorescent image: 
 299 587 114
1000m
R G BI + +=  (2) 
where red (R), green (G) and blue (B) correspond to the intensity values of the corresponding 
color components in the broadband image. Luminance was used in order to quantify the 
visual contrast observed by the human eye in the RGB image from the surgical microscope, 
since it is the current standard used by neurosurgeons for assessing the presence of 
fluorescence. It may be possible to optimize a camera setup for better contrast detection of 
fluorescence by selecting appropriate spectral detection bands, however the RGB camera used 
is from a commercial neurosurgical microscope for fluorescence-guided surgery, and so this 
represents the standard for comparison. For both tissue samples, the EMCCD fluorescence 
results in greater contrast ratios than the visible fluorescence obtained through the 
neurosurgical microscope in areas of high (box 1 in both images) as well as less visible 
fluorescence (box 2 in both images). The fiberoptic contact probe was used to measure a 
single location on each tissue sample corresponding to a location of high visible fluorescence 
on the microscope image, and the measured fluorescence from the probe was compared with 
the fluorescence recovered in a 5 by 5 pixel window at the same location in the EMCCD 
image (Fig. 5). 
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 Fig. 5. Correlation between the quantatitive PpIX fluorescence measured with the EMCCD 
system at 7 different locations (averaged over 5 by 5 pixel regions) and the corresponding 
quantitative point probe measurements. The linear regression line is also shown. 
There is good correlation between the EMCCD and probe data (R2 = 0.87), which allows 
the EMCCD thresholds in Section 3.A to be compared directly with the detection capabilities 
of the probe. The probe can detect PpIX concentrations as low as 1 ng/ml in vivo. Hence, 
since the EMCCD system (i) can detect as little as 8 ng/ml PpIX in phantoms, (ii) 
demonstrates linearity in fluorescence quantification for a range of concentrations and optical 
properties for exposure times as low as 5 ms, and (iii) shows strong correlation with the probe 
for fluorescence detection, indicating its detection capabilities are comparable to the highly 
sensitive point probe system, the clinical value of which has already been proven in high and 
low-grade glioma surgery [29]. 
4. Discussion 
We have demonstrated that a spectroscopic EMCCD-based imaging system out-performs the 
state-of-the-art sCMOS-based imaging system currently used in ALA-PpIX fluorescence-
guided tumor resection. Its higher detection sensitivity translates directly into an ability to 
detect substantially lower ALA-PpIX concentrations. As demonstrated in clinical studies to 
date, reliable detection of lower fluorophore concentrations should translate into improved 
completeness of tumor resection, particularly in quantitative fluorescence imaging mode 
where the confounding effects of variable light attenuation by the tissue are minimized 
[6,20,32,33]. The increase in wide-field detection sensitivity can be achieved despite the 
added light losses (estimated ∼30%) from the imaging bundle between the camera and the 
microscope. The presence of non-specific signals from tissue autofluorescence and ambient 
light can limit the benefits associated with the enhanced sensitivity provided by EMCCD 
detection during surgical interventions. However, ambient light is minimized during 
fluorescence-guided surgeries and our clinical measurements with the probe system to date 
indicate that the autofluorescence intensity is considerably smaller than the PpIX emissions 
associated with gliomas [29]. Furthermore, the ex vivo tissue results demonstrate that the 
EMCCD system has improved fluorescence detection sensitivity under these conditions. 
Perhaps the most important finding in the phantom study is that wide-field fluorescence 
quantification can potentially achieve a level of sensitivity comparable to that obtained with a 
state-of-the-art quantitative point contact probe that is currently being used to guide glioma 
resection in clinical trials [20]. The lowest concentrations of PpIX (8 ng/ml) detected here are 
consistent with the concentrations found in low-grade gliomas using a clinically-validated 
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quantitative fluorescence-reflectance fiberoptic probe [6,10]. This indicates that the level of 
improved sensitivity for the EMCCD system is relevant for low-grade glioma surgery, 
especially since the noise floor of the system has not yet been reached at these concentrations. 
The EMCCD-based system performance will be tested in future studies in patients 
undergoing ALA-induced fluorescence-guided glioma resection. The ability to generate wide-
field images with the same level of disease detection sensitivity as currently achievable only 
in point-by-point mode is an important advantage in clinical practice. 
Acknowledgments 
This work was supported by the Canadian Foundation for Innovation (CFI), the Discovery 
Grant program from the Natural Sciences and Engineering Research Council of Canada 
(NSERC) and the Industrial Innovation and Scholarships program (partnered NSERC, Fonds 
de recherche du Québec - Nature et technologies – FRQNT and Nüvü Camēras). Additional 
support was provided by the US National Institutes of Health (R01 NS052274), Banque 
Nationale, Groupe de Recherche en Sciences et Technologies biomédicales (GRSTB), a 
Norris Cotton Cancer Center Prouty grant and a Hitchcock Foundation Pilot Project grant. 
 
#252150 Received 19 Oct 2015; revised 11 Nov 2015; accepted 16 Nov 2015; published 30 Nov 2015 
(C) 2015 OSA 1 Dec 2015 | Vol. 6, No. 12 | DOI:10.1364/BOE.6.005063 | BIOMEDICAL OPTICS EXPRESS 5074 
